Synthesis of Bulk Drugs and Chemicals for Preclinical and Clinical Studies

美国国家癌症研究所（NCI）癌症治疗与诊断部（DCTD）的发展治疗项目（DTP）负责开发具有抗癌活性的药物。这些药物通过药物开发小组（DDG）、干预措施开发快速获取（RAID）和NCI发现资源快速获取（RAND）等多种机制从各种同行评议的来源中产生。此外，开发项目可能来自临床显像剂和增强剂开发（DCIDE）计划、化学预防部（DCP）计划、1型糖尿病RAID计划（T1D-RAID）和NIH-RAID计划。NCI的校内项目也是开发化合物的来源。

The Developmental Therapeutic Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) conducts development of agents with anticancer activity. The agents arise from a variety of peer-reviewed sources via many mechanisms such as Drug Development Group (DDG), Rapid Access to Intervention Development (RAID), and Rapid Access to NCI Discovery Resources (RAND). In addition, development projects could arise from Development of Clinical Imaging Agents and Enhancers (DCIDE) program, Division of Chemoprevention (DCP) program, Type-1 Diabetes RAID program (T1D-RAID), and NIH-RAID program. The NCI intramural program has also been a source of compounds for development. The contractor provides services to manufacture a variety of the selected bulk compounds in multi-gram and/or kilogram scale. The prepared bulk material is to be used for preclinical toxicity studies, preformulation and clinical trials for the various cancer indications. Technical reports submitted by the contractors may be used to support Investigational New Drug Applications (IND) submitted to the US Food and Drug Administration (FDA). Contracts have been chosen as instruments to accomplish the goals of cancer drug development at the NCI.